Fragile X Syndrome and Premutation Disorders: New Developments and Treatments (Clinics in Developmental Medicine)
1911612379
9781911612377
Description:
This book covers both molecular and clinical aspects of Fragile X Syndrome (FXS) and premutation disorders so that new targeted treatments can be understood by clinicians and parents. It covers all premutation disorders including FXTAS, FXPOI and FXAND problems. The main focus is to help clinicians to give the best care possible to patients with FXS and to understand a multidisciplinary treatment approach. Underserved populations such as babies and toddlers with FXS and mothers with the full mutation are highlighted, including the treatments that can be beneficial to them. This book also discuss fragile X associated disorders as they impact the family whose proband has FXS. A highlight of this book is the international perspective on how different cultures deal with FXS and targeted treatments.
Best prices to buy, sell, or rent ISBN 9781911612377
Frequently Asked Questions about Fragile X Syndrome and Premutation Disorders: New Developments and Treatments (Clinics in Developmental Medicine)
The price for the book starts from $135.83 on Amazon and is available from 4 sellers at the moment.
If you’re interested in selling back the Fragile X Syndrome and Premutation Disorders: New Developments and Treatments (Clinics in Developmental Medicine) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Fragile X Syndrome and Premutation Disorders: New Developments and Treatments (Clinics in Developmental Medicine) book, the best buyback offer comes from and is $ for the book in good condition.
The Fragile X Syndrome and Premutation Disorders: New Developments and Treatments (Clinics in Developmental Medicine) book is in very low demand now as the rank for the book is 4,941,305 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.